NCT05403177Recruiting
Marathon of Hope Cancer Centres Network Study for Ontario (MOHCCN-O)
Source: ClinicalTrials.gov · Last updated 10 Jun 2026
Brief summary (registry, in English)
The Marathon of Hope Cancer Centres Network (MOHCCN) is a national network of cancer centres that pursue collaborative cancer research in precision medicine (an emerging approach for disease treatment and prevention that considers individual variability in DNA, environment and lifestyle) to accelerate the discovery of innovations and improve the health outcomes for cancer patients
- Status (registry)
- Recruiting
- Study type
- Observational
- Enrollment
- 500 (estimated)
- First submitted
- 30 May 2022
- Start date
- 23 Jun 2022
- Primary completion date
- Apr 2030
- Lead sponsor
- University Health Network, Toronto
- Diseases
- Prostate cancer, Head and neck cancer, Kidney cancer, Melanoma, Lung cancer, Pancreatic cancer, Colorectal cancer, Ovarian cancer
- NCT number
- NCT05403177
What you commit to
- Study type: Observational
- Planned participants: 500
- From 23 Jun 2022 to the primary completion date, Apr 2030
- 3 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other
- None.
Who the study is looking for
- Patients with histological and/or cytological confirmation of blood or solid tumor malignancies. For tumour types where pre-surgical biopsy is not routinely performed to confirm a pathologic diagnosis of cancer, patients may consent to this protocol, but eligibility must be confirmed after pathology is finalized demonstrating presence of malignancy
- All patients must be able to satisfy the required minimum data elements for the 15k gold standard cohort through:
- Already existing data that satisfies the minimal requirements of a gold standard case (refer to Table 1)
- Have sufficient biospecimens (tumor and/or blood samples) available for more comprehensive molecular and immunophenotypic characterization
- Patients who do not satisfy the required minimum data elements but would like to participate, maybe requested to donate blood and undergo a fresh biopsy if the archived Formalin-fixed paraffin-embedded (FFPE) samples are not available, or in cases where a fresh tumor biopsy is deemed necessary for molecular profiling.
- Participating patients must agree to share their anonymized clinical and genomic data
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (3)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Kingston Health Sciences Centre Coordinator of this site? Confirm its status | Kingston | Canada | Recruiting |
| Ottawa Health Research Institute Coordinator of this site? Confirm its status | Ottawa | Canada | Not yet recruiting |
| Princess Margaret Cancer Centre Coordinator of this site? Confirm its status | Toronto | Canada | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.